Status:
UNKNOWN
Mannitol as Adjunct Therapy for Childhood Cerebral Malaria
Lead Sponsor:
Makerere University
Conditions:
Cerebral Malaria
Eligibility:
All Genders
6-5 years
Phase:
PHASE3
Brief Summary
Cerebral malaria is a life-threatening complication of Plasmodium falciparum infection in African children and nonimmune travellers despite availability of quinine, the current drug of choice. Several...
Detailed Description
Cerebral malaria is a life-threatening complication of Plasmodium falciparum infection accounting for significant morbidity and mortality in African children despite availability of quinine, the curre...
Eligibility Criteria
Inclusion
- Children aged 6 months to 5 years admitted to the Mulago hospital acute care unit during the study period with cerebral malaria: (seizures and unarousable coma lasting more than 30 minutes after seizures have stopped, with asexual forms of P. falciparum on the blood film, with no other cause of coma) and whose carers gave informed consent.
Exclusion
- Children with evidence of having received any sedation within two hours prior to admission to the acute care unit.
- Also exclude children with clinical signs of pulmonary congestion, or heart failure, or renal disease, or shock
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2005
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT00113854
Start Date
October 1 2004
End Date
May 1 2005
Last Update
June 24 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Paediatrics and Child Health, Makerere Medical School
Kampala, Kampala, Uganda, P O Box 7072